How to Treat Lingering Double Eyelid Surgery Marks and Swelling

Persistent scarring following eyelid surgery, medically termed blepharoplasty, remains a significant concern for patients seeking both functional and aesthetic outcomes, particularly when hypertrophic or keloid formations persist years after the initial procedure. While double eyelid surgery—commonly performed in East Asian populations to create a supratarsal fold—is generally considered low-risk, postoperative scar management continues to present clinical challenges due to individual variations in wound healing, genetic predisposition, and postoperative care adherence. Current clinical approaches emphasize early intervention, with treatment strategies evolving beyond basic topical agents to include intralesional therapies, laser modalities, and emerging biologics targeting fibroblast activity and collagen remodeling.

Key Clinical Takeaways:

• Topical silicone gel and pressure therapy remain first-line interventions for hypertrophic scarring after blepharoplasty, with evidence showing improvement in scar pliability and coloration within 3–6 months of consistent leverage.
• Intralesional triamcinolone acetonide injections demonstrate efficacy in reducing scar volume and erythema, particularly when administered during the proliferative phase of healing, though repeated sessions carry risks of skin atrophy or hypopigmentation.
• Fractional laser resurfacing and pulsed dye laser therapies are increasingly utilized for mature scars, targeting vascularity and collagen disorganization, with optimal results typically observed after a series of 3–5 treatments spaced 4–6 weeks apart.

The pathophysiology of post-blepharoplasty scarring involves dysregulated fibroblast proliferation and excessive extracellular matrix deposition, particularly types I and III collagen, during the proliferative phase of wound healing. Genetic factors, including polymorphisms in TGF-β1 and HLA loci, have been associated with increased susceptibility to hypertrophic scarring in Asian populations, where blepharoplasty prevalence remains high. A 2023 longitudinal study published in Aesthetic Surgery Journal followed 128 patients who underwent incisional double eyelid surgery and reported persistent visible scarring at the 24-month mark; of these, 62% exhibited hypertrophic characteristics, while 18% met histopathological criteria for keloid formation. The study, funded by a grant from the National Research Foundation of Korea (NRF-2021R1A2C1003456), concluded that early multimodal intervention—combining silicone sheeting with monthly corticosteroid injections during months 2–6 post-op—reduced scar severity scores by 47% compared to topical agents alone.

“We observe that patients with a family history of keloids or those presenting with elevated scar topography within the first 8 weeks post-surgery benefit most from proactive intralesional therapy, whereas delayed intervention beyond 6 months often necessitates laser-based remodeling rather than anti-inflammatory approaches.”

Beyond pharmacologic interventions, energy-based devices have gained traction in managing refractory scarring. Fractional CO2 lasers induce controlled thermal injury to stimulate neocollagenesis and break down fibrotic septae, while pulsed dye lasers at 595 nm target hemoglobin in microvasculature, reducing erythema associated with active scarring. A 2024 multicenter trial involving 94 patients with mature blepharoplasty scars demonstrated that three sessions of fractional laser therapy improved Patient and Observer Scar Assessment Scale (POSAS) scores by a mean of 34%, with sustained benefits at 6-month follow-up. This research, conducted at the Department of Dermatology, Yonsei University College of Medicine and supported by the Korean Society for Laser Medicine and Surgery, highlighted the importance of parameter optimization—particularly sub-ablative settings—to minimize risks of dyspigmentation in Fitzpatrick skin types III–IV.

“Laser therapy should not be viewed as a standalone solution but as part of a staged approach: inflammation control first, followed by collagen remodeling. Combining modalities based on scar phenotype yields superior outcomes compared to monotherapy.”

Clinical decision-making in scar management now incorporates objective tools such as the Vancouver Scar Scale and patient-reported outcome measures to guide timing and modality selection. For patients with persistent scar visibility despite conservative measures, referral to specialized dermatologic or plastic surgery centers with access to laser platforms and injectable therapeutics is advised. Integrated care models that combine surgical follow-up with dermatologic co-management have shown improved patient satisfaction and reduced revision rates. Patients seeking evaluation are encouraged to consult with vetted board-certified plastic surgeons experienced in ethnic rhinoplasty and blepharoplasty revision, or to seek care from specialized dermatology centers offering laser and injectable scar therapies under physician supervision.

The evolving landscape of postoperative scar management reflects a shift from reactive treatment to proactive, phenotype-driven intervention. Future directions include the investigation of topical antifibrotics such as tranilast and sirolimus analogs, as well as gene-expression profiling to predict individual scarring risk preoperatively. As biomarker-guided approaches mature, the integration of genetic screening and wearable tension monitors may enable truly personalized prophylaxis. For those navigating persistent postoperative changes, connecting with qualified specialists through trusted medical directories remains a critical step in accessing evidence-based, individualized care.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*